Market closed · After hours · 6:42 PM ET
Last update: Nov 18, 2026, 6:18 PM ET
Madrigal Pharmaceuticals, Inc.
$398.08▼ 5.67% today
After Hours

Why Madrigal Pharmaceuticals, Inc. (MDGL) stock moved

Latest session▼ 5.7% · Nov 18, 2026 close

Why Madrigal Pharmaceuticals, Inc. (MDGL) fell 5.7% today, November 18, 2026

Madrigal Pharmaceuticals, Inc. (MDGL) fell 5.7% on November 18, 2026, closing at $398.08 versus $421.99 the prior session (close-to-close, from daily closes). After multiple law firms—Kirby McInerney LLP, Kaplan Fox, and Kessler Topaz—announced securities fraud investigations into the company and senior management for potential federal securities law violations. Source: FMP price data; BestStocks detection.

Updated
Prior close
$421.99
Nov 18, 2026 close
$398.08
Change (close-to-close)
−$23.91
−5.67%
As first detected · Nov 18, 2026, 4:39 PM ET

Madrigal Pharmaceuticals (MDGL) moved -5.41% from $420.86 to $398.08 on 2026-11-18 after multiple law firms—Kirby McInerney LLP, Kaplan Fox, and Kessler Topaz—announced securities fraud investigations into the company and senior management for potential federal securities law violations.

What to watch next: MDGL earnings scheduled for 2026-02-18 (consensus EPS estimate $1.43) and any updates to the status or scope of the ongoing securities investigations.

Source: FMP price data; BestStocks detection · percentages in this note are as captured at detection; the confirmed close-to-close move is shown above.

Earlier sessions that moved MDGL

  1. +8.3%An ongoing securities investigation announcement by Kaplan Fox (newsfilecorp.com).
  2. −8.1%After reporting Q3 2026 earnings. Read the November 3, 2026 analysis →
  3. −4.2%Driven by Bank of America Securities lowering its price target to $533 from $543 and maintaining a Neutral rating, citing a lack of near-term clinical catalysts in the sector (web_catalyst).
  4. +4.6%We checked news, earnings reports, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
  5. −3.2%Valuation reassessment rather than operational news.
  6. −3.1%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
  7. +5.2%Following major institutional investor disclosures in SEC 13F filings released August 26.

Madrigal Pharmaceuticals, Inc. (MDGL) shares tumbled 5.7% to $398.08 as of November 18, 2026, a significant decline from the prior close of $421.99. BestStocks flagged the session as a major change for MDGL. The move is tied to price move down. Below, we break down what changed for MDGL, why it matters for investors, how the stock reacted, and the catalysts on the calendar.

What happened

MDGL fell 5.7% to $398.08

Madrigal Pharmaceuticals (MDGL) moved -5.41% from $420.86 to $398.08 on 2026-11-18 after multiple law firms—Kirby McInerney LLP, Kaplan Fox, and Kessler Topaz—announced securities fraud investigations into the company and senior management for potential federal securities law violations. MDGL earnings scheduled for 2026-02-18 (consensus EPS estimate $1.43) and any updates to the status or scope of the ongoing securities investigations.

This summary describes the catalyst and move as first detected on Nov 18, 2026, 4:39 PM EST; the stock has continued trading since, so the current price and percentage move (shown above) may be larger or smaller than the figures here.
Material / EarningsMedium confidence
Rel. volume
1.8×
Above Avg
Vs peers
—
No comparable peers
Market cap
$9.2B
NASDAQ Global Select
Analyst target
$669
+68.1% vs price
Price chart
Oct 19 – Nov 18
ENNVNVEEFVN$396$432$468Oct 19Oct 27Nov 3Nov 11Nov 18
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details

What it means for Madrigal Pharmaceuticals, Inc. investors

For Madrigal Pharmaceuticals, Inc. investors, the recent signals add up to a strong bearish shift. On the constructive side: Positive price momentum. Weighing against that: Material negative event; Sharp 5.7% decline — elevated risk. Wall Street's consensus price target sits at $669.22, implying +68.1% upside from $398.08. BestStocks rates the overall signal quality medium (65/100). With earnings roughly 92 days out, the next report is the most likely near-term test of the move.

MDGL price reaction

MDGL last traded at $398.08, down $23.91 (-5.67%) from the previous close of $421.99. The session traded on 1.8× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $396.32 and $467.54, and it currently sits about 2% of the way up that band.

Bullish and bearish analyst opinions on Madrigal Pharmaceuticals, Inc. (MDGL)

Latest catalysta bearish counterpoint
The latest catalyst — a materially negative development — a bearish counterpoint that challenges the prevailing bullish analyst view.

The consensus analyst price target on Madrigal Pharmaceuticals, Inc. (MDGL) is $669.22, 68.1% above the recent $398.08. Over the past 90 days analysts logged 0 upgrades, 3 maintains, and 0 downgrades. Here is how the bullish and bearish cases on MDGL line up.

The bullish case

  • Wall Street's consensus price target of $669.22 implies +68.1% upside from $398.08.
  • The Street's most bullish target is $962.00 (+141.7%).
  • Positive price momentum.

The bearish case

  • Material negative event.
  • Sharp 5.7% decline — elevated risk.
  • Madrigal Pharmaceuticals (MDGL) declined 2.60% to $455.03, driven primarily by technical weakness and valuation reassessment rather than operational news.
Bull vs bear balanceStrong Bearish Shift
BearishNeutralBullish
The latest catalyst moved the balance toward the bears — the hollow tick marks where it sat before.

Weighing both sides, BestStocks' composite read of recent signals is strongly bearish, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.

Analyst price targets and ratings are FMP consensus figures as of Nov 18, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.

Analyst expectations
Consensus target: $669+68.1%
= 3 maintains
Canaccord Genuity maintained Buy · 2026-11-04
SEC filings watch
8-K2026-11-03
Material event — review for impact
high
10-Q2026-11-03
Quarterly financial results
medium
8-K2026-08-12
Material event — review for impact
high
8-K2026-07-30
Material event — review for impact
high
Peer context
MDGL-5.7%

Previous notable changes for MDGL

News2026-11-14
Law firm Kessler Topaz initiates securities investigation into Madrigal Pharmaceuticals for potential federal securities law violations.
News2026-11-13+0.5%
Madrigal Pharmaceuticals scheduled to participate in fireside chats at three upcoming investor conferences.
News2026-11-11+0.1%
Law firm Hagens Berman investigates MDGL for alleged clinical data integrity concerns based on whistleblower allegations.
Activity2026-11-09+8.3%via defenseworld.net ↗
Madrigal Pharmaceuticals rose 6.42% to $425.27, reversing earlier pressure from a reported reduction in Candriam S.C.A.'s position (defenseworld.net) and an ongoing securities investigation announcement by Kaplan Fox (newsfilecorp.com). Volume of 86,420 shares ran at 1.02x the time-adjusted historical average, suggesting normal trading interest despite the investigative headwind.
Upcoming catalysts & outlook
Next earnings
2027-02-18 (est.)
in 92 days
Earnings Release
2027-02-18
High impact
Thesis shift
Strong Bearish Shift
bearish signal
Risk level
High
from change events

Frequently asked questions about MDGL

Why did Madrigal Pharmaceuticals, Inc. (MDGL) stock move?

Madrigal Pharmaceuticals, Inc. (MDGL) fell 5.7% on November 18, 2026, closing at $398.08 versus $421.99 the prior session (close-to-close, from daily closes). After multiple law firms—Kirby McInerney LLP, Kaplan Fox, and Kessler Topaz—announced securities fraud investigations into the company and senior management for potential federal securities law violations. Source: FMP price data; BestStocks detection.

How much did MDGL stock fall?

MDGL lost 5.67% ($23.91) versus the prior close of $421.99, last trading at $398.08 on 1.8× average volume.

When is Madrigal Pharmaceuticals, Inc.'s next earnings date?

MDGL's next earnings report is estimated for 2027-02-18 — about 92 days away.

What is the analyst price target for MDGL?

The consensus analyst price target for MDGL is $669.22, about 68.1% above the current $398.08. Over the past 90 days, analysts recorded 0 upgrades, 3 maintains, and 0 downgrades.

How BestStocks tracks MDGL

This page is generated automatically by BestStocks' change-detection system after price move down was detected and verified against independent data sources. It draws on 20 tracked change events for MDGL, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 18, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.

Data sources
FMP real-time & historical price dataCompany news feedsFMP earnings & estimatesSEC EDGAR filingsAnalyst ratings & price targets (FMP)Earnings calendar (FMP)
Educational research tool — not personalized investment advice. Data may be delayed.